Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. (Q38246305)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

3 references

14 September 2020

8 February 2021

6 July 2021

Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

14 September 2020

1 reference

8 February 2021

ATP-binding cassette transporter

1 reference

6 July 2021

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Pranav Gupta

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Rishil J Kathawala

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Atish Patel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

John N D Wurpel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Zhe-Sheng Chen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

English

0 references

publication date

4 September 2014

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

14 September 2020

8 February 2021

6 July 2021

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

14 September 2020

8 February 2021

6 July 2021

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

13848-13877

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

16 February 2020

copyright license

3 references

14 September 2020

8 February 2021

6 July 2021

0 references

Receptor protein-tyrosine kinases and their signal transduction pathways

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Tyrosine kinase blockers: new hope for successful cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Fusion oncogenes in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Mechanisms of cancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Ceramide glycosylation potentiates cellular multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

DNA repair pathways in drug resistance in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

The human ATP-binding cassette (ABC) transporter superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

ABC transporter architecture and mechanism: implications from the crystal structures of BtuCD and BtuF.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Mammalian ABC transporters in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

The role of ABC transporters in drug resistance, metabolism and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

ABC Transporters: From Microorganisms to Man

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Structure and mechanism of ABC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

The structure of Escherichia coli BtuF and binding to its cognate ATP binding cassette transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Revisiting the ABCs of multidrug resistance in cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Evolution of ATP-binding cassette transporter genes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

ABC transporters, drug resistance, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Role of the breast cancer resistance protein (ABCG2) in drug transport

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Overview: ABC transporters and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

ABC transporters, mechanisms and biology: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

The mechanism of action of multidrug-resistance-linked P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Transportomics: screening for substrates of ABC transporters in body fluids using vesicular transport assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Multidrug resistance in oral squamous cell carcinoma: The role of vacuolar ATPases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Multidrug resistance and the role of P-glycoprotein knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

The Role of ABC Transporters in Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

ABCC10, ABCC11, and ABCC12.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Multidrug resistance associated proteins in multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Ontogeny of sulfonylurea-binding regulatory subunits of K(ATP) channels in the pregnant rat myometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

A family of drug transporters: the multidrug resistance-associated proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

The MRP family of drug efflux pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10)

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Identification of ABCG2 dysfunction as a major factor contributing to gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

ABCG2: determining its relevance in clinical drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Localisation of breast cancer resistance protein in microvessel endothelium of human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

A multidrug resistance transporter from human MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Complete characterization of the human ABC gene family.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Purification of breast cancer resistance protein ABCG2 and role of arginine-482.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Imatinib resistance in multidrug-resistant K562 human leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Imatinib is a substrate for various multidrug resistance proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Reversing multidrug resistance by tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Tyrosine kinase inhibitors-ZD1839 (Iressa).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190913848

The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane

21 January 2018

1 reference

12 December 2020

The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)

1 reference

12 December 2020

The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux

1 reference

12 December 2020

Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

1 reference

12 December 2020

Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.

1 reference

12 December 2020

Erlotinib (Tarceva): an update on the clinical trial program

1 reference

12 December 2020

Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.

1 reference

12 December 2020

Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation.

1 reference

12 December 2020

Tyrosine kinases as targets for cancer therapy

1 reference

12 December 2020

Clinical Relevance of Immunohistochemical Detection of Multidrug Resistance P-Glycoprotein in Breast Carcinoma

1 reference

12 December 2020

Defeating drug resistance in cancer

1 reference

12 December 2020

Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs.

1 reference

12 December 2020

Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein.

1 reference

12 December 2020

Chemotherapy-induced resistance by ATP-binding cassette transporter genes.

1 reference

12 December 2020

Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2

1 reference

12 December 2020

Roles of multidrug resistance genes in breast cancer chemoresistance

1 reference

12 December 2020

Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: development of in vitro high-speed screening systems

1 reference

12 December 2020

Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition

1 reference

12 December 2020

The ATPase activities of sulfonylurea receptor 2A and sulfonylurea receptor 2B are influenced by the C-terminal 42 amino acids

1 reference

12 December 2020

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.

1 reference

12 December 2020

First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group

1 reference

12 December 2020

Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells

1 reference

12 December 2020

Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells.

1 reference

12 December 2020

Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.

1 reference

12 December 2020

Expression of a multidrug resistance gene in human cancers

1 reference

12 December 2020

Nucleotide binding by membrane components of bacterial periplasmic binding protein-dependent transport systems

1 reference

12 December 2020

Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells

1 reference

12 December 2020

1 reference

12 December 2020

P-glycoprotein in adult hematologic malignancies.

1 reference

12 December 2020

P-glycoprotein in adult solid tumors. Expression and prognostic significance.

1 reference

12 December 2020

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

1 reference

12 December 2020

Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes

1 reference

12 December 2020

10.3390/MOLECULES190913848

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

PubMed publication ID

25191874

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25191874%20AND%20SRC:MED&resulttype=core&format=json